Nathan Leader

A recent review in @NEJM discusses sudden cardiac arrest management in athletes. Read the Key Points and a comment from Deputy Editor Ann Cheung, MD, MBA, MS: nej.md/4a3IjtR #cardiology

New advances in risk assessment and management are shaping updates across international cholesterol guidelines. This forecast highlights shifts in interpretation, thresholds, and treatment strategies to better prevent ASCVD worldwide. 🔗 ow.ly/185V50Y6E1G #Cholesterol

🔴Myocarditis & look-alikes: when the diagnosis matters @Heart_BMJ #Cardiology #CardioEd #Myocarditis

Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of #HeartFailure and Pulmonary Hypertension: A Scientific Statement From the @AHAScience ahajournals.org/doi/10.1161/HH… @CircHF #HFpEF

Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Read this State-of-the-Art review in #EHJ 👉 ow.ly/Ze0p50XqmPK @RoccoMontone @ehj_ed

OCEAN trial: For AF patients with ≥1 risk factor post-catheter ablation, low-dose rivaroxaban showed similar rates of stroke/systemic embolism and major bleeding at 3 years compared to aspirin. #AHA25 View the slides here: clinicaltrialresults.org/wp-content/upl…

What a strange conclusion for this article. I'd edit it to: Among older nursing home residents with frailty who were receiving treatment with antihypertensive agents and had a systolic blood pressure below 130 mm Hg, an antihypertensive treatment step-down strategy was safe. H/T @AndrewFoy82 Reduction of Antihypertensive Treatment in Nursing Home Residents | New England Journal of Medicine nejm.org/doi/full/10.10…

Early Surgery for Asymptomatic Severe MR @SahminL ahajournals.org/doi/full/10.11…

You don't need to be a competitive athlete to have an athlete's heart. Regular exercise—especially over 5 hours weekly—reshapes the heart, boosting health and performance. bit.ly/3Gor9Lp

🗞️ Impact of genotype–phenotype associations on prognosis in #DilatedCardiomyopathy @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd bit.ly/4nuVZBN

Pre-participation screening in competitive athletes in Italy: an analysis of real-world practice from a large database academic.oup.com/eurjpc/advance… #preparticipationscreening #ECG #Sportscardiology #athlete

Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: thelancet.com/journals/lance…

#ESCCongressVisuals from Hot Line 3👇 Given the progress made in the management of acute myocardial infarctions, it is important to understand whether beta blockers still have a role in those with mildly reduced EF. Will the REBOOT trial demonstrate a reduction in the rates of death, reinfarction or hospital admission for heart failure? 👇 The large combined Danish (DANBLOCK) and Norwegian (BETAMI) randomised beta-blocker trials provide evidence on the use of beta blockers post-MI in patients with preserved EF. Will there be a reduction in a composite of recurrent MI, all cause mortality, malignant VT, cardiac arrest and HF? 👇 REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: This large meta-analysis provides the largest dataset to date to determine the efficacy of beta blockers in improving outcomes post-MI in those with mildly reduced EF. 👇 Will noninvasive assessment permit identification of high risk post-MI patients with preserved LV function? How will ICD use post-MI change after the results are shared? Will this trial impact guidelines? 👇 #ESCCongress

#ESCCongressVisuals from Hot Line 5👇 DANCANVAS 2 attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease amongst individuals of low social status. 👇 PREVENT-MINS is a multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective is to determine the impact of ivabradine on the risk of MI in patients 30 days after noncardiac surgery 👇 The ABC-AF study evaluates whether a personalized treatment recommendation strategy-guided by the biomarkers improves outcomes in AF. How generalizable is this study? 👇 Patients with acute VTE in the setting of transient provoking factors are treated with short-term anticoagulation. However, the risk of recurrence may increase if there are enduring risk factors. Will patients receiving extended treatment of apixaban reduce recurrence rates? HI-PRO is a single-center, double-blind randomized trial that answers this question. 👇 #ESCCongress #ESCCongressVisuals

WITHDRAW-AF RCT 📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration 👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m #EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD

Lipid management remains key in preventing #ASCVD. While statins are foundational, nonstatin therapies are expanding fast. This expert panel reviews current international recommendations regarding lipid management. jacc.org/doi/10.1016/j.… #cvLipids #JACCAdvances

📉Lower LDL-C for longer is better. The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C. Read the guidelines & recommendations: lipidjournal.com/article/S1933-…. @LipidCNS @CBallantyneMD

📌 Figure illustrating 👉 Causes of AF in the young 👫 #afib #EPeeps #CardioTwitter #MedTwitter #SportsCardiology #Review #ECG @shivkumarmd @DrJasonAndrade @DhirajGuptaBHRS @SSharmacardio @tomdepotter @ecgrhythms @mmamas1973 @SeguraCardio @gonzaeperez @ErinMichos @Hragy @ftrae

A Gift from the Heart. Our community thanks the Broderick family for their leadership and philanthropy. @LibinInstitute @HotchkissBrain @UCalgaryMed

Distinguishing athlete’s heart from #cardiomyopathy? 🫀 ✅ GLS & RV strain usually preserved in athletes ⚠️ ⬇️GLS or RV strain = 🚩 for HCM/ARVC 🧠 LA strain, morphologic/TDI + #CMR can help 📎: jacc.org/doi/10.1016/j.… #ACCAthleticHeart #EchoFirst #JACCIMG #SportsCardio #cvHCM